<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000560928"><TermName>canertinib</TermName><TermPronunciation>(can-ER-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. Canertinib blocks the action of proteins called epidermal growth factor receptors, and may cause cancer cells to die. It is a type of tyrosine kinase inhibitor. Also called canertinib dihydrochloride and CI-1033.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000721182" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;canertinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000721181" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;canertinib&quot;" language="es" id="_4"/><SpanishTermName>canertinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. El canertinib bloquea la acción de las proteínas llamadas receptores del factor de crecimiento epidérmico y puede destruir las células cancerosas. Es un tipo de inhibidor de la tirosina cinasa. También se llama CI-1033 y diclorhidrato de canertinib.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-11-30</DateFirstPublished><DateLastModified>2008-01-09</DateLastModified></GlossaryTerm>
